Trial Profile
Evaluation of effectiveness and therapeutic response to Preductal OD 80 mg in daily practical use for chronic stable angina pectoris
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Oct 2022
Price :
$35
*
At a glance
- Drugs Trimetazidine (Primary)
- Indications Angina pectoris; Coronary artery disease
- Focus Therapeutic Use
- Acronyms ODA
- Sponsors Servier
- 23 Aug 2018 New trial record
- 13 Aug 2018 Results published in the Advances in Therapy